

Miriam Koopman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7923169/publications.pdf>

Version: 2024-02-01

136
papers

7,662
citations

117625

34
h-index

54911

84
g-index

136
all docs

136
docs citations

136
times ranked

9800
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	6.3	2
2	Rationale and design of the PROMETCO study: a real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective. <i>Future Oncology</i> , 2022, 18, 1313-1320.	2.4	2
3	Baseline treatment patterns of the first 277 patients in PROMETCO: A real-world, prospective, longitudinal cohort study on the continuum of care in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 55-55.	1.6	0
4	Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 1001.	3.7	2
5	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	3
6	Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). <i>Clinical Colorectal Cancer</i> , 2022, 21, 154-166.	2.3	6
7	External validation of the MSKCC nomogram to estimate five-year overall survival after surgery for stage III colon cancer in a Dutch population. <i>Acta Oncologica</i> , 2022, 61, 560-565.	1.8	0
8	Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. <i>BMC Cancer</i> , 2022, 22, 394.	2.6	7
9	Cell-Free Circulating (Tumor) DNA before Surgery as a Prognostic Factor in Non-Metastatic Colorectal Cancer: A Systematic Review. <i>Cancers</i> , 2022, 14, 2218.	3.7	16
10	External Validation of Two Established Clinical Risk Scores Predicting Outcome after Local Treatment of Colorectal Liver Metastases in a Nationwide Cohort. <i>Cancers</i> , 2022, 14, 2356.	3.7	3
11	Translation of IDEAS trial results into clinical practice: Analysis of the implementation of a new guideline for colon cancer. <i>International Journal of Cancer</i> , 2022, 151, 1270-1279.	5.1	5
12	Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data. <i>International Journal of Cancer</i> , 2021, 148, 296-306.	5.1	27
13	Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era. <i>British Journal of Cancer</i> , 2021, 124, 399-406.	6.4	19
14	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	3.2	3
15	Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study. <i>International Journal of Cancer</i> , 2021, 148, 2702-2711.	5.1	3
16	Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199571.	3.2	3
17	Perceived Care and Well-being of Patients With Cancer and Matched Norm Participants in the COVID-19 Crisis. <i>JAMA Oncology</i> , 2021, 7, 279.	7.1	56
18	The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care. <i>Scientific Reports</i> , 2021, 11, 3923.	3.3	13

#	ARTICLE	IF	CITATIONS
19	<i>BRAF</i> V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1386-1395.	6.3	17
20	Dose-Response and Dose-Toxicity Relationships for Glass ⁹⁰ Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1616-1623.	5.0	36
21	Interaction Between Primary Tumor Resection, Primary Tumor Location, and Survival in Synchronous Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 315-324.	1.3	8
22	Disease recurrence after colorectal cancer surgery in the modern era: a population-based study. <i>International Journal of Colorectal Disease</i> , 2021, 36, 2399-2410.	2.2	42
23	Patient-derived organoids as a predictive biomarker for treatment response in cancer patients. <i>Npj Precision Oncology</i> , 2021, 5, 30.	5.4	111
24	A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research. <i>Cancer Treatment Reviews</i> , 2021, 95, 102174.	7.7	15
25	Colorectal Cancer Care and Patient's Perceptions Before and During COVID-19: Implications for Subsequent SARS-CoV-2 Infection Waves. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab047.	2.9	3
26	Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases. <i>JAMA Surgery</i> , 2021, 156, 710-720.	4.3	34
27	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	6.3	12
28	Clinical outcomes of biliary drainage of malignant biliary obstruction due to colorectal cancer metastases: A systematic review. <i>European Journal of Internal Medicine</i> , 2021, 88, 81-88.	2.2	4
29	Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1726-1734.	2.5	0
30	Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102226.	7.7	8
31	Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2124766.	5.9	2
32	Comparing Modeling Approaches for Discrete Event Simulations With Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer. <i>Value in Health</i> , 2021, 25, 104-115.	0.3	2
33	Role of Up-Front Primary Tumor Resection and Tumor Sidedness in the Survival of Synchronous Metastatic Colon Cancer Patients. <i>Digestive Surgery</i> , 2021, 38, 283-289.	1.2	1
34	Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment. <i>JAMA Surgery</i> , 2021, 156, 1093.	4.3	34
35	Mismatch Repair Status in Patient-Derived Colorectal Cancer Organoids Does Not Affect Intrinsic Tumor Cell Sensitivity to Systemic Therapy. <i>Cancers</i> , 2021, 13, 5434.	3.7	5
36	Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real-world data. <i>International Journal of Cancer</i> , 2020, 146, 2968-2978.	5.1	8

#	ARTICLE	IF	CITATIONS
37	Loss of skeletal muscle index and survival in patients with metastatic colorectal cancer: Secondary analysis of the phase 3 CAIRO3 trial. <i>Cancer Medicine</i> , 2020, 9, 1033-1043.	2.8	23
38	The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival. <i>Annals of Surgical Oncology</i> , 2020, 27, 1580-1588.	1.5	38
39	Model-based evaluation of the cost effectiveness of 3 versus 6 months' adjuvant chemotherapy in high-risk stage II colon cancer patients. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482095411.	3.2	3
40	European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment. <i>European Journal of Cancer</i> , 2020, 138, 99-108.	2.8	8
41	Duration of adjuvant treatment for patients with stage III colon cancer. <i>Lancet Oncology</i> , 2020, 21, 1545-1547.	10.7	1
42	Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 240.	2.4	4
43	Practice Variation in the Adjuvant Treatment of Colon Cancer in the Netherlands: A Population-based Study. <i>Anticancer Research</i> , 2020, 40, 4331-4341.	1.1	4
44	Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer. <i>Cells</i> , 2020, 9, 2688.	4.1	10
45	Management of cytotoxic chemotherapy-induced hand-foot syndrome. <i>Oncology Reviews</i> , 2020, 14, 442.	1.8	56
46	Modeling Personalized Adjuvant Treatment in Early stage colon cancer (PATTERN). <i>European Journal of Health Economics</i> , 2020, 21, 1059-1073.	2.8	5
47	Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework. <i>Clinical Cancer Research</i> , 2020, 26, 4892-4900.	7.0	5
48	Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study. <i>Acta Oncologica</i> , 2020, 59, 395-403.	1.8	6
49	The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 919-928.	7.3	15
50	Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review. <i>Pharmacoeconomics</i> , 2020, 38, 683-713.	3.3	10
51	Clinical implications of assumptions in cost-effectiveness analyses of systemic therapies for metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, e16021-e16021.	1.6	0
52	Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program. <i>Journal of Clinical Oncology</i> , 2020, 38, 7009-7009.	1.6	0
53	Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival based on real-life data. <i>Journal of Clinical Oncology</i> , 2020, 38, 32-32.	1.6	0
54	The Prospective Dutch Colorectal Cancer (PLCRC) Cohort: Towards a unique patient-reported outcome enriched 'real-world' data cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 52-52.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Receipt and survival outcomes by age following second-line therapy for metastatic CRC (mCRC): Analysis of 5,289 patients from the ARCAD Clinical Trials Program.. Journal of Clinical Oncology, 2020, 38, 6-6.	1.6	2
56	Mode of progression after radioembolization in patients with colorectal cancer liver metastases. EJNMMI Research, 2020, 10, 107.	2.5	3
57	The era of alternative designs to connect randomized clinical trials and real-world data. Nature Reviews Clinical Oncology, 2019, 16, 589-589.	27.6	7
58	Evaluation of Continuous Tumor-Sizeâ€‘Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Network Open, 2019, 2, e1911750.	5.9	6
59	Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients. American Journal of Clinical Nutrition, 2019, 110, 1395-1403.	4.7	15
60	Choosing the right strategy based on individualized treatment effect predictions: combination versus sequential chemotherapy in patients with metastatic colorectal cancer. Acta OncolÃ³gica, 2019, 58, 326-333.	1.8	3
61	Angiogenesis in 90Y-Radioembolization of Colorectal Liver Metastases. Seminars in Nuclear Medicine, 2019, 49, 204-210.	4.6	5
62	Health-related quality of life in rectal cancer patients undergoing neoadjuvant chemoradiation with delayed surgery versus short-course radiotherapy with immediate surgery: a propensity score-matched cohort study. Acta OncolÃ³gica, 2019, 58, 407-416.	1.8	18
63	Genome-wide cell-free DNA fragmentation in patients with cancer. Nature, 2019, 570, 385-389.	27.8	764
64	Skeletal muscle mass loss and doseâ€‘limiting toxicities in metastatic colorectal cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 803-813.	7.3	65
65	Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer. JNCI Cancer Spectrum, 2019, 3, plz014.	2.9	10
66	Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer, 2019, 19, 390.	2.6	83
67	Implementation, participation and satisfaction rates of a web-based decision support tool for patients with metastatic colorectal cancer. Patient Education and Counseling, 2019, 102, 1331-1335.	2.2	9
68	Comparing Strategies for Modeling Competing Risks in Discrete-Event Simulations: A Simulation Study and Illustration in Colorectal Cancer. Medical Decision Making, 2019, 39, 57-73.	2.4	10
69	Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group. Clinical Colorectal Cancer, 2019, 18, e229-e230.	2.3	4
70	A cost analysis of upfront DPYD genotypeâ€‘guided dose individualisation in fluoropyrimidine-based anticancer therapy. European Journal of Cancer, 2019, 107, 60-67.	2.8	65
71	Recent changes in overall survival of real-life stage IV colorectal cancer patients.. Journal of Clinical Oncology, 2019, 37, 3522-3522.	1.6	6
72	Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in the Netherlands: A population-based study.. Journal of Clinical Oncology, 2019, 37, 6612-6612.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. <i>Journal of the National Cancer Institute</i> , 2018, 110, 638-648.	6.3	90
74	The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 737-744.	1.9	8
75	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. <i>European Journal of Cancer</i> , 2018, 96, 115-124.	2.8	2
76	Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer. <i>Clinical Pharmacokinetics</i> , 2018, 57, 455-473.	3.5	14
77	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 2052-2060.	1.6	26
78	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <i>Nature Communications</i> , 2018, 9, 4112.	12.8	55
79	Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. <i>Cancer Epidemiology</i> , 2018, 57, 60-67.	1.9	18
80	DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. <i>Lancet Oncology</i> , The, 2018, 19, 1459-1467.	10.7	238
81	Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. <i>British Journal of Cancer</i> , 2018, 119, 1244-1251.	6.4	57
82	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018, 100, 35-45.	2.8	29
83	Monitoring potentially modifiable lifestyle factors in cancer survivors: A narrative review on currently available methodologies and innovations for large-scale surveillance. <i>European Journal of Cancer</i> , 2018, 103, 327-340.	2.8	8
84	Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 909-919.	7.3	42
85	Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm. <i>European Journal of Cancer</i> , 2017, 81, 130-134.	2.8	14
86	Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. <i>European Journal of Cancer</i> , 2017, 76, 93-99.	2.8	54
87	From tumour heterogeneity to advances in precision treatment of colorectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 235-246.	27.6	466
88	Survival after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced colorectal liver metastases: A case-matched comparison with palliative systemic therapy. <i>Surgery</i> , 2017, 161, 909-919.	1.9	51
89	Evaluating the scientific basis of quality indicators in colorectal cancer care: A systematic review. <i>European Journal of Cancer</i> , 2017, 86, 166-177.	2.8	12
90	Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials. <i>British Journal of Cancer</i> , 2017, 117, 1768-1776.	6.4	10

#	ARTICLE	IF	CITATIONS
91	Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry. <i>Clinical Cancer Research</i> , 2017, 23, 387-398.	7.0	128
92	Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models. <i>BMC Medical Research Methodology</i> , 2017, 17, 170.	3.1	19
93	Impact of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) on time to progression and overall survival (OS) in metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10087-10087.	1.6	4
94	Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 63140-63154.	1.8	19
95	An individual patient data (IPD) meta-analysis of the impact of thrombocytosis (↑plts) on overall survival (OS) whilst using an intermittent chemotherapy (iCTx) strategy in advanced colorectal cancer (aCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, e15044-e15044.	1.6	0
96	<i>WRN</i> Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 4612-4622.	7.0	9
97	Palliative resection of the primary tumor is associated with improved overall survival in incurable stage IV colorectal cancer: A nationwide populationâ€based propensityâ€score adjusted study in the Netherlands. <i>International Journal of Cancer</i> , 2016, 139, 2082-2094.	5.1	55
98	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology</i> , The, 2016, 17, 1709-1719.	10.7	442
99	Significant increase of synchronous disease in first-line metastatic colorectal cancer trials: Results of a systematic review. <i>European Journal of Cancer</i> , 2016, 69, 166-177.	2.8	12
100	Developing a core set of patient-reported outcomes in pancreatic cancer: A Delphi survey. <i>European Journal of Cancer</i> , 2016, 57, 68-77.	2.8	33
101	Management of liver metastases in colorectal cancer patients: A retrospective case-control study of systemic therapy versus liver resection. <i>European Journal of Cancer</i> , 2016, 59, 13-21.	2.8	50
102	Insights into the Doseâ€Response Relationship of Radioembolization with Resin ⁹⁰Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1014-1019.	5.0	88
103	Costâ€effectiveness in colorectal cancer: challenges on quality and comparability. <i>Colorectal Cancer</i> , 2016, 5, 21-31.	0.8	3
104	Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3640-3640.	1.6	1
105	The CAIRO4 study: The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancerâ€A randomized phase III study of the Dutch Colorectal Cancer Group (DCCG).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS782-TPS782.	1.6	0
106	Prognostic value of primary tumor resection in synchronous metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of first-line randomized trials from the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2016, 34, 658-658.	1.6	0
107	¹⁹â€F MRSI of capecitabine in the liver at 7â€T using broadband transmitâ€receive antennas and dualâ€band RF pulses. <i>NMR in Biomedicine</i> , 2015, 28, 1433-1442.	2.8	13
108	Systemic Treatment: Maintenance Compared with Holiday. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 85-90.	3.8	3

#	ARTICLE	IF	CITATIONS
109	EMAST Is Associated with a Poor Prognosis in Microsatellite Instable Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0124538.	2.5	28
110	Reduced rate of copy number aberrations in mucinous colorectal carcinoma. Oncotarget, 2015, 6, 25715-25725.	1.8	11
111	Maintenance treatment in metastatic colorectal cancer. Lancet Oncology, The, 2015, 16, e582-e583.	10.7	4
112	Randomized controlled trial for pre-operative dose-escalation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial. Trials, 2015, 16, 58.	1.6	55
113	Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet, The, 2015, 385, 1843-1852.	13.7	421
114	Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncology, The, 2015, 16, 1639-1650.	10.7	277
115	RE: Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors. Journal of the National Cancer Institute, 2015, 107, djv104-djv104.	6.3	0
116	MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. Oncotarget, 2015, 6, 22996-23007.	1.8	34
117	The CAIRO4 study: The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – A randomized phase III study of the Dutch Colorectal Cancer Group (DCCG).. Journal of Clinical Oncology, 2015, 33, TPS3630-TPS3630.	1.6	0
118	Genomic landscape of metastatic colorectal cancer. Nature Communications, 2014, 5, 5457.	12.8	61
119	Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2014, 759, 37-44.	1.0	11
120	Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies. Clinical Cancer Research, 2014, 20, 5322-5330.	7.0	561
121	Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, 3504-3504.	1.6	15
122	Final results and subgroup analyses of the phase 3 CAIRO3 study: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2014, 32, LBA388-LBA388.	1.6	16
123	Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncologica, 2013, 52, 950-955.	1.8	51
124	Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).. Journal of Clinical Oncology, 2013, 31, 3502-3502.	1.6	29
125	Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3552-3552.	1.6	0
126	Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: A retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncologica, 2012, 51, 831-839.	1.8	37

#	ARTICLE	IF	CITATIONS
127	Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature. <i>Indian Journal of Surgical Oncology</i> , 2012, 3, 57-65.	0.7	1
128	Prognostic Value of Resection of Primary Tumor in Patients with Stage IV Colorectal Cancer: Retrospective Analysis of Two Randomized Studies and a Review of the Literature. <i>Annals of Surgical Oncology</i> , 2011, 18, 3252-3260.	1.5	158
129	Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2009, 360, 563-572.	27.0	1,243
130	Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. <i>European Journal of Cancer</i> , 2009, 45, 1999-2006.	2.8	82
131	A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?. <i>European Journal of Cancer</i> , 2009, 45, 1935-1949.	2.8	87
132	Chemotherapy, which drugs and when. <i>European Journal of Cancer</i> , 2009, 45, 50-56.	2.8	15
133	Reversible Posterior Leukoencephalopathy Syndrome Caused by Bevacizumab: Report of a Case. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 1425-1426.	1.3	23
134	Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. <i>Lancet</i> , The, 2007, 370, 135-142.	13.7	593
135	Evaluation of an individual feedback report on patient-reported outcomes in the Prospective Dutch ColoRectal Cancer cohort. <i>Supportive Care in Cancer</i> , 0, , .	2.2	0
136	Clinical Outcomes of Biliary Drainage in Patients with Malignant Biliary Obstruction Caused by Colorectal Cancer Metastases. <i>Journal of Gastrointestinal Cancer</i> , 0, , .	1.3	0